ArticleBasic and clinical neuroscience2025
Vismodegib Improved Therapy of Medulloblastoma by Targeting Sonic Hedgehog Signaling Pathway on DAOY Medulloblastoma Cell Line.
Article in Basic and clinical neuroscience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Targeting smoothened (SMO) has been a remarkable strategy for treating sonic hedgehog (Shh)-dependent cancers, especially medulloblastoma. GDC-0449, also known as vismodegib, is a potent SMO inhibitor with mild toxicity and high affinity. Thus, this study aimed to investigate the anti-medulloblastoma efficacy of vismodegib in the DAOY medulloblastoma cell line. Methods: Human DAOY medulloblastoma cells were cultured in Dulbecco's Modified Eagle's Medium (DMEM). 50, 80, 100, and 150 μM doses of vismodegib were used to treat cells. 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), scratch, and trypan blue assays, as well as real-time polymerase chain reaction (RT-PCR) and immunofluorescence studies, were performed 24 and 48 h post-treatment. Results: The MTT and trypan blue assays showed a significant difference in viability between the control and treatment groups. The results of the scratch assay showed that in the control group, the cells were able to repair the lesion, while the scratch disintegrated at higher doses of vismodegib. The expression of Conclusion: The results of the current study confirm that vismodegib is a potent inhibitor of the Shh pathway and may be used in combination with new therapeutic methods to treat medulloblastoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.